ClinicalTrials.gg
CompletedNCT02247739Updated Dec 8, 2017Results posted

A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

A Phase 2 interventional study of Recombinant human C1 inhibitor and Placebo in Hereditary Angioedema, sponsored by Pharming Technologies B.V.. Completed at 10 sites in 7 countries. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2017-12-08.

Sponsored by Pharming Technologies B.V. (part of Pharming Group N.V.) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. Complement C1 Inhibitor Protein · Angioedemas, Hereditary.

Enrollment
9th of 17
32 · median 32
Started
2014
the only one that year
Phase 2
2 of 17
none open now
Registered
15th of 17
by date
Lead sponsor
4 of 17
Pharming Technologies B.V.

Among the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary, this one is the 9th largest by enrollment, is the only one that started in 2014, is one of 2 in phase 2, and was the 15th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

None of the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →

About Complement C1 Inhibitor Protein

Complement C1 Inhibitor Protein: first FDA approval 2014 (Ruconest), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary as a file.
02

Study summary

Primary Objective:

To evaluate the efficacy of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of angioedema attacks in patients with HAE

Secondary Objective:

To evaluate the safety and immunogenicity of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of angioedema attacks in patients with HAE

Read the detailed description

Study Design:

This is a multi-center, randomized, double-blind, placebo-controlled, 3-period crossover study of rhC1INH in prophylaxis of angioedema attacks in patients with HAE.

Medical screening (clinical and laboratory parameters) will be performed and patient medical history specific to HAE attacks will be collected to assess eligibility. Each patient will receive three 4 week periods of treatment twice weekly.

03

Conditions studied

  • Hereditary Angioedema

Keywords

  • HAE
  • Hereditary Angioedema
  • Prophylaxis
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients fulfilling the following criteria at Screening are eligible for participation in the study:

  1. Age 13 years or older
  2. Laboratory confirmed diagnosis of HAE
  3. A history of frequent HAE attacks (at least 4 attacks per month across a minimum of 3 consecutive months).
  4. Female patients of who are sexually active must be willing to use an acceptable form of .
  5. Provided written (and written assent for minors)
  6. Willingness and ability to comply with all protocol procedures

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria at Screening are to be excluded from study participation:

  1. Patients with medical history of allergy to rabbits or rabbit-derived products (including rhC1INH)
  2. Diagnosis of acquired angioedema (AAE)
  3. Patients who are pregnant, or breastfeeding, or are currently intending to become pregnant
  4. Treatment with any drug in the past 30 days
  5. Patients with any condition or treatment that, in the opinion of the Investigator, might interfere with the evaluation of study objectives
  6. Patients currently treated with angiotensin-converting enzyme (ACE) inhibitors
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    rhC1INH twice weekly

    rhC1INH administered twice weekly

    Biological: Recombinant human C1 inhibitor

  • Experimental
    rhC1INH once weekly

    rhC1INH administered once weekly

    Biological: Recombinant human C1 inhibitor

  • Placebo comparator
    Placebo (Saline) twice weekly

    Placebo (Saline) administered twice weekly

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of HAE Attacks

    Average number of HAE attacks normalized to a 28 day period

    Time frame: 28 days

Secondary outcomes

  1. Number of Participants With Adverse Events

    Number of participants that experienced Treatment Emergent Adverse Events observed in safety population

    Time frame: 20 weeks

  2. Percentage of Participants Achieving at Least 50% Reduction in Number of Attacks

    Percentage of participants achieving at least 50% reduction in the number of attacks normalized to a 28-day period as compared to the placebo treatment period

    Time frame: 28 days

Other outcomes

  1. Immunogenicity

    Number of participants analyzed for neutralizing C1INH-specific antibodies and neutralizing rhC1INH-specific antibodies after confirmed anti-C1INH and anti rhC1INH IgM or IgG antibodies

    Time frame: 20 weeks

07

Results

Posted Dec 8, 2017

Participant flow

Participant flow — Overall Study
MilestoneTreatment Sequence ATreatments Sequence BTreatment Sequesce CTreatment Sequence DTreatment Sequence ETreatment Sequence F
Started565565
Completed534554
Not completed031011

Outcome measures

PrimaryNumber of HAE Attacks

Average number of HAE attacks normalized to a 28 day period

Time frame:
28 days
Reported as:
Mean · attacks
Number of HAE Attacks
attacksrhC1INH Twice WeeklyrhC1INH Once WeeklyPlacebo (Saline) Twice Weekly
Number of HAE Attacks2.74 (1.8 to 3.7)4.36 (3.1 to 5.6)7.18 (5.8 to 8.6)
SecondaryNumber of Participants With Adverse Events

Number of participants that experienced Treatment Emergent Adverse Events observed in safety population

Time frame:
20 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsrhC1INH Twice WeeklyrhC1INH Once WeeklyPlacebo (Saline) Twice Weekly
Number of Participants With Adverse Events10138
SecondaryPercentage of Participants Achieving at Least 50% Reduction in Number of Attacks

Percentage of participants achieving at least 50% reduction in the number of attacks normalized to a 28-day period as compared to the placebo treatment period

Time frame:
28 days
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least 50% Reduction in Number of Attacks
percentage of participantsrhC1INH Twice WeeklyrhC1INH Once Weekly
Percentage of Participants Achieving at Least 50% Reduction in Number of Attacks74 (57 to 86)42 (26 to 59)
Other pre-specifiedImmunogenicity

Number of participants analyzed for neutralizing C1INH-specific antibodies and neutralizing rhC1INH-specific antibodies after confirmed anti-C1INH and anti rhC1INH IgM or IgG antibodies

Time frame:
20 weeks
Reported as:
Count of participants · Participants
Immunogenicity
ParticipantsrhC1INH Twice WeeklyrhC1INH Once WeeklyPlacebo (Saline) Twice Weekly
Immunogenicity000

Adverse events

Collected over 20 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rhC1INH Twice Weekly—1/29 (3.4%)5/29 (17.2%)
rhC1INH Once Weekly—0/29 (0%)7/29 (24.1%)
Placebo (Saline) Twice Weekly—0/28 (0%)2/28 (7.1%)
Most frequent serious events
Most frequent serious events
EventrhC1INH Twice WeeklyrhC1INH Once WeeklyPlacebo (Saline) Twice Weekly
PhimosisCongenital, familial and genetic disorders1/290/290/28
Most frequent other events
Most frequent other events
EventrhC1INH Twice WeeklyrhC1INH Once WeeklyPlacebo (Saline) Twice Weekly
HeadacheNervous system disorders5/292/290/28
NasopharyngitisInfections and infestations0/293/292/28
AnxietyPsychiatric disorders0/292/290/28

Baseline characteristics

Population is intention to treat (ITT) population

Age, Categorical
Age, Categorical(Participants)All Study Participants
<=18 years1
Between 18 and 65 years28
>=65 years3
Age, Continuous
Age, Continuous(years)All Study Participants
Mean46 (17 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female26
Male6
Region of Enrollment
Region of Enrollment(participants)All Study Participants
Canada2
Czech Republic2
Romania6
United States7
Macedonia, The Former Yugoslav Republic of8
Italy1
Serbia2
Israel4
08

Study locations

10 sites
  • University of South Florida Asthma, Allergy and Immunology Clinical Research Unit
    Tampa, Florida 33613, United States
  • University of South Florida, Asthma, Allergy & Immunology Clinical Research Unit
    Tampa, Florida 33613, United States
  • Washington University Division of Allergy and Immunology
    Saint Louis, Missouri 63141, United States
  • Baker Allergy, Asthma and Dermatology Research Center
    Lake Oswego, Oregon 97035, United States
  • Ottawa Allergy Research Corp
    Ottawa, Ontario K1G6C6, Canada
  • Faculty Hospital by St. Anna Brno, Department of clinical Immunology and Allergology
    Brno, 65691, Czechia
  • Azienda Ospedaliera Universitaria Luigi Sacco Di Milano
    Milan, 20157, Italy
  • PHI University Clinic of Dermatology
    Skopje, 1000, Macedonia, The Former Yugoslav Republic of
  • SC Centrul Clinic Mediquest SRL
    Sângeorgiu de Mureş, Mures 547530, Romania
  • Clinical Center Serbia
    Belgrade, Serbia
09

References and documents

Publications

  • Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K. Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2. PubMed 36326435 ↗
  • Riedl MA, Grivcheva-Panovska V, Moldovan D, Baker J, Yang WH, Giannetti BM, Reshef A, Andrejevic S, Lockey RF, Hakl R, Kivity S, Harper JR, Relan A, Cicardi M. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet. 2017 Sep 30;390(10102):1595-1602. doi: 10.1016/S0140-6736(17)31963-3. Epub 2017 Jul 25. PubMed 28754491 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of May 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2017, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2014
First posted
Sep 25, 2014
Start
Dec 2014
Primary completionActual
May 2016
CompletionActual
Sep 2016
Results first posted
Dec 8, 2017
Last update
Dec 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02247739
Responsible party
Sponsor
First posted
Sep 25, 2014
Start date
Dec 2014
Primary completion
May 2016
Completion
Sep 2016
Results posted
Dec 8, 2017
Last update
Dec 8, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Complement C1 Inhibitor Protein · Conestat alfa · C1 esterase inhibitor (human)

Start the discussion